Results 91 to 100 of about 11,363,143 (293)

Editorial: Higher-Order Conditioning: Beyond Classical Conditioning

open access: yesFrontiers in Behavioral Neuroscience, 2022
Busquets Garcia, Arnau, 1985-   +1 more
openaire   +3 more sources

The QCD heavy-quark potential to order v^2: one loop matching conditions

open access: yes, 2000
The one-loop QCD heavy quark potential is computed to order v^2 in the color singlet and octet channels. Several errors in the previous literature are corrected.
A. Czarnecki   +52 more
core   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Conditional model order estimation [PDF]

open access: yesIEEE Transactions on Signal Processing, 2001
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
openaire   +2 more sources

Higher-order conditions for strict efficiency revisited [PDF]

open access: yes
D. V. Luu and P. T. Kien propose in Soochow J. Math. 33 (2007), 17-31, higher- order conditions for strict efficiency of vector optimization problems based on the derivatives introduced by I. Ginchev in Optimization 51 (2002), 47-72.
Ivan Ginchev
core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Positive Definiteness of High-Order Subdifferential and High-Order Optimality Conditions in Vector Optimization Problems

open access: yesAbstract and Applied Analysis, 2013
We obtain a new Taylor's formula in terms of the order subdifferential of a function from to . As its applications in optimization problems, we build order sufficient optimality conditions of this kind of functions and order necessary conditions ...
He Qinghai, Zhang Binbin
doaj   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy